New developments in locally advanced nonsmall cell lung cancer

Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer

(2020) D. De Ruysscher et al.   ANNALS OF ONCOLOGY

Place de l’immunothérapie dans le cancer bronchique non à petites cellules localement avancé

(2020) A. Levy et al.   Cancer Radiotherapie

Dose to Highly Functional Ventilation Zones Improves Prediction of Radiation Pneumonitis for Proton and Photon Lung Cancer Radiation Therapy

(2020) Shannon O’Reilly et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Postoperative intensity‐modulated radiation therapy reduces local recurrence and improves overall survival in III‐N2 non‐small‐cell lung cancer: A single‐center, retrospective study

(2020) Wei Wei et al.   Cancer Medicine

Left Ventricular Systolic Dysfunction Is a Possible Independent Risk Factor of Radiation Pneumonitis in Locally Advanced Lung Cancer Patients

(2020) Guoxin Cai et al.   Frontiers in Oncology

Patient-reported outcome measures in definitive chemoradiation for non-small cell lung cancer

(2020) Khinh Ranh Voong et al.   Translational Lung Cancer Research

A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer

(2020) Elizabeth J. Cathcart-Rake et al.   Clinical Lung Cancer

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non–Small-Cell Lung Cancer

(2020) Hirotsugu Kenmotsu et al.   JOURNAL OF CLINICAL ONCOLOGY

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.

(2020) Yi-Long Wu et al.   JOURNAL OF CLINICAL ONCOLOGY

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.

(2020) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

(2020) Catherine A Shu et al.   LANCET ONCOLOGY

Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial

(2020) Ursula Nestle et al.   LANCET ONCOLOGY

Radiation Recall Pneumonitis Induced by Anti-PD-1 Blockade: A Case Report and Review of the Literature

(2020) Yu Chen et al.   Frontiers in Oncology

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

(2020) L. Paz-Ares et al.   ANNALS OF ONCOLOGY

Effects of Postoperative Radiotherapy on Survival of Patients With Stage IIIA Resected Non–Small Cell Lung Cancer: Analysis of the SEER Database

(2020) Fei Gao et al.   Journal of the National Comprehensive Cancer Network

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

(2019) Solange Peters et al.   ANNALS OF ONCOLOGY

Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non–Small Cell Lung Cancer

(2019) Alexander Sun et al.   JAMA Oncology

Real-world outcomes in patients with unresected stage III non-small cell lung cancer

(2019) Kellie J. Ryan et al.   MEDICAL ONCOLOGY

Prognostic value of volumetric metabolic parameter changes determined by during and after radiotherapy‐based 18 F‐FDG PET/CT in stage III non‐small cell lung cancer

(2019) Helen H. W. Chen et al.   KAOHSIUNG JOURNAL OF MEDICAL SCIENCES

The Relationship between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients with Advanced Non-Small Cell Lung Cancer

(2019) Khinh Ranh Voong et al.   Clinical Lung Cancer

Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer

(2019) Seok-Hyun Kim et al.   BRITISH JOURNAL OF CANCER

Neoadjuvant Tyrosine Kinase Inhibition in Locally-advanced Non-small Cell Lung Cancer: Two Cases and a Brief Literature Review

(2019) ANISH B. PARIKH et al.   ANTICANCER RESEARCH

Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes

(2019) Senthil Rajappa et al.   ADVANCES IN THERAPY

Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small cell lung cancer

(2019) Ramaswamy Govindan et al.   CURRENT MEDICAL RESEARCH AND OPINION

The impact of epidermal growth factor receptor mutations on the efficacy of definitive chemoradiotherapy in patients with locally advanced unresectable stage III non-small cell lung cancer: a systematic review and meta-analysis

(2019) Qin Qin et al.   Expert Review of Anticancer Therapy

The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy

(2019) Lu Chen et al.   INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING

Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC

(2019) Karolina Edlund et al.   Journal of Thoracic Oncology

Predicting radiation pneumonitis in locally advanced stage II–III non-small cell lung cancer using machine learning

(2019) José Marcio Luna et al.   RADIOTHERAPY AND ONCOLOGY

Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non–Small Cell Lung Cancer

(2019) Shaun M. O'Brien et al.   Cancer Immunology Research

Current status of immune checkpoint inhibition in early-stage NSCLC

(2019) J Vansteenkiste et al.   ANNALS OF ONCOLOGY

Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients

(2019) Kazutaka Hosoya et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Prognostic variables associated with improved outcomes in patients with stage III NSCLC treated with chemoradiation followed by consolidation Pembrolizumab: a subset analysis of a phase II study from the Hoosier Cancer Research Network LUN 14-179

(2019) Bilal Anouti et al.   Clinical Lung Cancer

Predictive and prognostic role of metabolic response in patients with stage III NSCLC treated with neoadjuvant chemotherapy

(2019) Angelo Castello et al.   Clinical Lung Cancer

Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy

(2019) Colton J. Ladbury et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

(2019) Wen-Zhao Zhong et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial

(2019) S. Peters et al.   LUNG CANCER

Interdisciplinary multimodality management of stage III nonsmall cell lung cancer

(2019) Rudolf M. Huber et al.   European Respiratory Review

Prognostic Value of the Volumetric Parameters of Dual–Time-Point 18F-FDG PET/CT in Non–Small Cell Lung Cancer Treated With Definitive Radiation Therapy

(2019) Eiichiro Okazaki et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment

(2019) LUKAS KÄSMANN et al.   ANTICANCER RESEARCH

Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer

(2019) Kazue Yoneda et al.   BRITISH JOURNAL OF CANCER

Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?

(2019) Sanjal Desai et al.   Current Oncology Reports

The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients

(2019) Huijuan Li et al.   Translational Lung Cancer Research

Prospective assessment of demographic characteristics associated with worse health related quality of life measures following definitive chemoradiation in patients with locally advanced non-small cell lung cancer

(2019) Jennifer Vogel et al.   Translational Lung Cancer Research

Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer

(2019) Wan Ling Tan et al.   Journal of Thoracic Oncology

Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy

(2019) Eun-Ah Choe et al.   LUNG CANCER

Prognostic value of post-induction chemotherapy 18F-FDG PET-CT in stage II/III non-small cell lung cancer before (chemo-) radiation

(2019) Julien Ganem et al.   PLoS One

Endobronchial Ultrasound for the Diagnosis of Centrally Located Lung Tumors: A Systematic Review and Meta-Analysis

(2019) Jolanda C. Kuijvenhoven et al.   RESPIRATION

Image-based lung functional radiotherapy planning for non-small cell lung cancer

(2019) Faegheh S. Mounessi et al.   STRAHLENTHERAPIE UND ONKOLOGIE

Prevalence and Characteristics of Symptomatic Pneumonitis After Radiotherapy of Patients With Locally Advanced Lung Cancer

(2019) DIRK RADES et al.   ANTICANCER RESEARCH

Image-guidance triggered adaptive replanning of radiation therapy for locally advanced lung cancer: an evaluation of cases requiring plan adaptation

(2019) Sarit Appel et al.   BRITISH JOURNAL OF RADIOLOGY

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer

(2019) Jeffrey D. Bradley et al.   JOURNAL OF CLINICAL ONCOLOGY

Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

(2019) Willem J. A. Witlox et al.   PHARMACOECONOMICS

Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer

(2019) Liming Sheng et al.   Radiation Oncology

Pulmonary function decreases moderately after accelerated high‐dose irradiation for stage III non‐small cell lung cancer

(2019) Brane Grambozov et al.   Thoracic Cancer

Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer

(2018) Tina Cascone et al.   ANNALS OF THORACIC SURGERY

Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer

(2018) Whitney S. Brandt et al.   ANNALS OF THORACIC SURGERY

Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer

(2018) Si-si Wang et al.   Cellular & Molecular Immunology

Efficacy of Endosonographic Procedures in Mediastinal Restaging of Lung Cancer After Neoadjuvant Therapy

(2018) Valliappan Muthu et al.   CHEST

How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience

(2018) Olarn Roengvoraphoj et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non–Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study

(2018) Dirk De Ruysscher et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections

(2018) Enrico Munari et al.   Journal of Thoracic Oncology

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR -mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

(2018) Wen-Zhao Zhong et al.   LANCET ONCOLOGY

A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer

(2018) Jean-Paul Sculier et al.   LUNG CANCER

Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: Implications for adjuvant therapy

(2018) Mitsuhiro Isaka et al.   LUNG CANCER

Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer

(2018) Erkan Topkan et al.   LUNG CANCER

The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer

(2018) Kevin Jao et al.   LUNG CANCER

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer

(2018) Jessika A. Contreras et al.   RADIOTHERAPY AND ONCOLOGY

Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells

(2018) Shaohua Cui et al.   Journal of Cancer

Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer

(2018) Justin Yeh et al.   Journal of Thoracic Disease

Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy

(2018) Sawsan Rashdan et al.   Lancet Respiratory Medicine

Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer

(2018) O. Ercelep et al.   Clinical & Translational Oncology

A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non–small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L)

(2018) Hiroaki Akamatsu et al.   Clinical Lung Cancer

Significance of 18F-FDG PET Parameters According to Histologic Subtype in the Treatment Outcome of Stage III Non–small-cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy

(2018) Eunji Kim et al.   Clinical Lung Cancer

Analysis of Relapse Events After Definitive Chemoradiotherapy in Locally Advanced Non–Small-Cell Lung Cancer Patients

(2018) G. Daniel Grass et al.   Clinical Lung Cancer

Discovery of pre-therapy 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients

(2018) Mubarik A. Arshad et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer

(2018) Siddhartha Devarakonda et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early stage squamous cell lung carcinoma

(2018) Hui Yu et al.   Journal of Thoracic Oncology

Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer

(2018) Jun Yeun Cho et al.   LUNG CANCER

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer

(2018) Antoine Schernberg et al.   PLoS One

Prehabilitation in thoracic surgery

(2018) David Sanchez-Lorente et al.   Journal of Thoracic Disease

Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non–Small-Cell Lung Cancer

(2018) Addie Hill et al.   Journal of Oncology Practice

Immunotherapy in patients with early stage resectable nonsmall cell lung cancer

(2018) Katrien Ghysen et al.   CURRENT OPINION IN ONCOLOGY

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer

(2018) Nathan A. Pennell et al.   JOURNAL OF CLINICAL ONCOLOGY

Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis

(2018) Teppei Yamaguchi et al.   LUNG CANCER

Prognostic and Added Value of Echocardiographic Strain for Prediction of Adverse Outcomes in Patients with Locally Advanced Non-Small Cell Lung Cancer after Radiotherapy

(2018) Lu Chen et al.   ULTRASOUND IN MEDICINE AND BIOLOGY

Quantitative severity of pulmonary emphysema as a prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer

(2018) Seung Jun Lee et al.   Thoracic Cancer

Impact of tumor infiltrating lymphocytes and lymphoid follicle formation on patient survival following surgery for lung squamous cell carcinoma

(2018) Morimichi Nishihira et al.   Thoracic Cancer

Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non–Small Cell Lung Cancer in the Context of the US Health Care System

(2018) Steven D. Criss et al.   JAMA Oncology

Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer

(2018) Akira Ono et al.   LUNG CANCER

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update

(2017) Mark G. Kris et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer

(2017) Olarn Roengvoraphoj et al.   STRAHLENTHERAPIE UND ONKOLOGIE

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer

(2016) Elisabeth Brambilla et al.   JOURNAL OF CLINICAL ONCOLOGY

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

(2016) Peter Goldstraw et al.   Journal of Thoracic Oncology

GILT—A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer

(2016) Michael Flentje et al.   STRAHLENTHERAPIE UND ONKOLOGIE

Prognostic Factors as a Function of Disease-free Interval After Definitive (Chemo)radiation for Non–Small Cell Lung Cancer Using Conditional Survival Analysis

(2015) Jidong Hong et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study

(2013) Glenwood D. Goss et al.   JOURNAL OF CLINICAL ONCOLOGY

Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer

(2011) Alice De Sanctis et al.   CANCER

ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)

(2009) A. Brunelli et al.   EUROPEAN RESPIRATORY JOURNAL

Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023

(2008) Karen Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY